Market Overview

Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades

Share:
Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades
Related CNCE
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut
34 Biggest Movers From Yesterday

Concert Pharmaceuticals Inc (NASDAQ: CNCE) announced Friday the Patent Trial and Appeal Board decided not to grant the company a Post Grant Review petition in the patent '335 dispute with Incyte Corporation (NASDAQ: INCY).

The Analyst

Mizuho Securities' Difei Yang decided to downgrade the stock from Buy to Neutral and maintained the price target at $23.

The Thesis

The stock traded sharply lower on the news about the patent '335 dispute, but the decision isn't going to have implications for the ultimate outcome of the trial, said Yang, though she expects the litigation overhang will remain in the foreseeable future. The analyst sees the stock as fairly valued and decided to leave unchanged her peak revenue estimates of $130 million in 2028 for CTP-543 and $110 million in 2028 for AVP-786.

Two of Concert's Phase 3 trials are now expected in 2019 instead of 2018, and a new neurology candidate could be disclosed by 2Q 2018, said Yang. The new drug could lead to a higher stock price.

Price Action

The stock plunged more than 27 percent after the release of the news and recently traded around $20.

Related Links:

Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making

Key Takeaways From The JPMorgan Healthcare Conference

Latest Ratings for CNCE

DateFirmActionFromTo
Sep 2018Janney CapitalInitiates Coverage OnNeutral
May 2018H.C. WainwrightMaintainsBuyBuy
Mar 2018H.C. WainwrightMaintainsBuyBuy

View More Analyst Ratings for CNCE
View the Latest Analyst Ratings

Posted-In: Difei Yang Mizuho SecuritiesAnalyst Color Biotech Downgrades Health Care Analyst Ratings General Best of Benzinga

 

Related Articles (INCY + CNCE)

View Comments and Join the Discussion!
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Signet Jewelers' Blemishes Lead To RBC Downgrade

Bank Of America On AMD, Nvidia, And Intel's 'Processor-Gate'